A year-long extended release nanoformulated cabotegravir prodrug
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
[HTML][HTML] Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …
2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis
Preexposure prophylaxis (PrEP) with antiretrovirals (ARV) can prevent human
immunodeficiency virus (HIV) transmission, but its efficacy is highly dependent on strict …
immunodeficiency virus (HIV) transmission, but its efficacy is highly dependent on strict …
Creation of a long-acting rilpivirine prodrug nanoformulation
Antiretroviral therapy requires lifelong daily dosing to attain viral suppression, restore
immune function, and improve quality of life. As a treatment alternative, long-acting (LA) …
immune function, and improve quality of life. As a treatment alternative, long-acting (LA) …
Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs
In spite of introduction of combination antiretroviral therapy (cART) against human
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
Novel bilayer microarray patchassisted longacting microdepot cabotegravir intradermal delivery for HIV preexposure prophylaxis
Injectable longacting cabotegravir (CAB LA) is effective and safe for preexposure HIV
prophylaxis. It is recently approved for clinical use in those at high risk of contracting HIV …
prophylaxis. It is recently approved for clinical use in those at high risk of contracting HIV …
[HTML][HTML] Development of dissolving microneedles for intradermal delivery of the long-acting antiretroviral drug bictegravir
Oral administration and intramuscular (IM) injection are commonly recommended options for
human immunodeficiency virus (HIV) treatment. However, poor patient compliance due to …
human immunodeficiency virus (HIV) treatment. However, poor patient compliance due to …
Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis
Hydrogel-forming microarray patches (HF-MAPs) offer minimally invasive, pain-free and
prolonged drug delivery. These devices are designed to be self-administered and self …
prolonged drug delivery. These devices are designed to be self-administered and self …
Formulation and pharmacology of long-acting cabotegravir
C Trezza, SL Ford, W Spreen, R Pan… - Current Opinion in HIV …, 2015 - journals.lww.com
Formulation and pharmacology of long-acting cabotegravir : Current Opinion in HIV and AIDS
Formulation and pharmacology of long-acting cabotegravir : Current Opinion in HIV and AIDS …
Formulation and pharmacology of long-acting cabotegravir : Current Opinion in HIV and AIDS …